China's Medical and Health Sector Sees Over 100 Financing Deals in December 2025 Amid Surge in Innovation

　　【Pharmaceutical Network Industry Dynamics】With the continuous breakthroughs in cutting-edge technologies and the advancement of excellent pipelines, China's medical and health industry is constantly掀起ing a financing热潮 to accelerate towards a new stage of high-quality development, address unmet clinical needs, and enhance global competitiveness. According to incomplete statistics, in December 2025, there were 182 financing events (excluding IPOs, etc.) in the global medical and health field, with a disclosed total amount of approximately US$5.362 billion. Among them, 102 events took place in China, amounting to about US$2.08 billion.
 

By December 17, 2025, StairMed has completed its B+ round of financing. It focuses on the research, development, and application of minimally invasive implantable brain-computer interface technology, making it another company globally—after Musk's Neuralink—to enter the clinical stage in invasive brain-computer interfaces. The funds from this round of financing will provide strong support for subsequent product iterations and large-scale clinical applications.
 

On December 16, Suzhou Jishu Medical Technology Co., Ltd. announced the completion of its Series A financing. This round of financing will mainly be used for Jishu Medical's R&D investment, market expansion, and team building in the field of eye disease treatment and prevention.
 

On December 16, Beijing Zheyuan Technology Co., Ltd. announced the completion of a hundred-million-yuan A+ round of financing. This round of financing will mainly be used to deepen the construction of the company's artificial intelligence-driven new drug research and development platform, expand the technical boundaries of combining computational biology with drug discovery, and advance the implementation of internal R&D pipelines and international cooperation projects.
 

On December 15, Beijing Bohui Biotechnology Co., Ltd. announced the successful completion of a nearly RMB 100 million Series A+ financing round. The funds raised will be mainly used to accelerate the clinical progress of the company's core projects, expand the preclinical R&D pipeline, and comprehensively push the company towards a new phase of clinical development and internationalization.
 

On December 15, Suzhou Baifu Laser Technology Co., Ltd. completed its C-round financing. This C-round financing will mainly be used for product research and development, market expansion, and capacity improvement of Suzhou Baifu Laser, further consolidating its advantageous position in the field of mid-to-high-end medical aesthetic devices produced in China.
 

In addition, KYinno, a new drug R&D service platform, has completed a 250-million-yuan B-round financing, which will be mainly used to accelerate the co-development and clinical advancement of multiple First-in-Class (FIC) and Best-in-Class (BIC) bispecific/multi-specific antibody drugs under the company's portfolio; Chengdu Peptide Biotech, an innovative peptide drug R&D company, received tens of millions of yuan in A-round financing, which will advance the core pipeline R&D for pain, cardiovascular, and respiratory system diseases, while deploying large-scale artificial intelligence (AI)-assisted peptide drug development technology...
 

From an overall perspective, the financing activities in China's healthcare sector in 2025 show significant signs of "structural recovery." These funds are expected to inject more momentum into the development of China's pharmaceuticals industry, driving resources toward innovation and clinical value, and accelerating the process of domestic substitution and internationalization. In the next 3-5 years, the industry will enter a virtuous cycle of "R&D - capital - commercialization."
 

Notably, these financings will also accelerate the integration and differentiation of China's pharmaceutical industry. In the future, capital will favor companies that truly possess source innovation and global commercialization potential; companies lacking differentiated pipelines or core technologies will face greater financing difficulties and elimination pressure. Meanwhile, the efficient use of financing funds will also drive companies to focus more on addressing "unmet clinical needs," shifting from past "me-too innovation" to pursuing "global firsts" and "best-in-class."
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.